Experience Beats Everything

The superheros of the Medical Cannabis Bio Pharmaceutical Industry

MMJ BioPharma is a bio-pharmaceutical company that is focused on developing pioneering cannabis medications. The ultimate goal is to produce non-addictive Food and Drug Administration (FDA)-approved pain management drugs. Our approach is biological as opposed to that of the traditional pharmaceutical company which is chemical.

We are aware that innovative medicines keep patients healthy and out of the hospital, reducing the need for costly medical care and more. As a major player in the biopharmaceutical industry, MMJ is honored to be part of this biopharmaceutical innovation that is driving contributions to the world economy.

Our approach is scientific based as we continue to work with the FDA and DEA in our strategic drug development plan. Medicines are enabling us to more effectively treat the biggest cost driver in health care: chronic disease. Medicines play a central role in making our health care system more sustainable. Use of medicines can help patients avoid other costlier services, such as emergency room visits, hospital stays, surgeries and long-term care.

MMJ to date has developed a patent-pending compound for symptomatic treatment of Multiple Sclerosis (MS), Huntington’s Disease, and several other conditions. The company has initiated an FDA approval process for the MS indication as well as an approval process for Huntington’s Disease and for several other drugs that are presently in development.

History

The parent company, MMJ Holdings Incorporated, as founded in 2015 and is privately owned. The company has operations in both the US and Jamaica. MMJ prides itself in having a culture of diversity, integrity and a commitment to helping others. MMJ is honored to have as part of its team, some of the world’s leading minds in medical and pharmaceutical research.

The company’s founder, Duane Boise, is a well-known business entrepreneur who has a passion for helping patients with serious unmet medical needs. He is intent on doing this with medicines which have the potential to make a real difference in the lives of others.

Management

MMJ has assembled a team of world-known neurologists, genomic experts, bio-informaticians, experts in drug formulation, chemists, clinicians, researchers, and big pharma veterans.

Timothy C. Moynahan, Executive Chairman of the Board of Directors

Mr. Moynahan is an accomplished attorney who also serves as the Chairman of the Exec. Board of the Global Virus Network a global authority for the control of viral diseases. Mr. Moynahan also serves on the Advisory Board and Exec. Committee of Institute of Human Virology (IHV) a center of the University of Maryland Biotechnology Institute, affiliated with the University of Maryland School of Medicine that is dedicated to the research and prevention of chronic viral diseases and virally linked cancers. Director, Robert Gallo, M.D., is the co-discoverer of the AIDS virus.


Duane Boise, President & CEO

Mr. Boise is a successful business entrepreneur who was the former CEO of Falkirk Hospital (NY). He was the co-founder of the St. Vincent DePaul Homeless Shelter, the first AIDS Hospice in the United States. Mr. Boise was also the founder of the EMED a comprehensive emergency medical evacuation system throughout Jamaica, the Caribbean, Central and South America. He brings more than 25 years of experience in the medical services industry and strong international business background with the ability to establish relationships and organize operations under the most demanding conditions and circumstances.


Dr. Brian Mcllroy-Chief Scientific Officer

Dr. Brian Mcllroy is a senior executive with more than 20 years of experience in the life science/biotechnology arena. He is a passionate change agent who excels at the intersection of technology and commercial business, providing market sought solutions across the healthcare industry.

Dr. Mcllroy’s broad expertise includes driving new product development with demonstrated success across multiple areas including economic development, advanced technology development, new drug evaluation, investigational clinical research & commercialization.

He has a proven track record of success in taking multidimensional complex problems and creating achievable milestones through: R&D, Marketing, Licensing (in & out) and Business Development.

Dr. Mcllroy was the Executive Director at the Buffalo Institute for Genomics and Data Analytics. Other career highlights include-the Managing Director of Alliance Management at GE Ventures and the Commercial Development Leader-Healthcare at GE Ideaworks.

Dr. Mcllroy has a PHD in Medical Biophysics-Photodynamic Therapy from the University of London and a BSC in Laser Physics from the University of St. Andrews.

Dr. Elio P. Mariani –Director of Research and Development

Dr. Elio Marianihas forty years experience in Pharmaceutical Sciences that includes development of all dosage forms, manufacturing processes for oral solids, oral liquid, topical semi-solid systems, parenteral formulation, transdermal delivery and novel drug delivery.

Dr. Mariani’s formulation processes have been followed from laboratory development through commercial manufacturing. His scientific input has been provided to various business development functions to ensure acceptability of the product attributes.

Dr. Mariani’s managerial experience has encompassed multiple disciplines in all areas of pharmaceutical science. His organizational skills have been highly successful in developing an infrastructure in scientific affairs.

He was the chief executive responsible for Scientific Affairs at KV Pharmaceutical company and the Senior Vice President of Research and Development as well as a member of the Board of Directors for Hercon Laboatories Corporation.

Dr. Mariani has a Doctorate of Philosophy in pharmaceutical chemistry, a Bachelor of Science in pharmacy and a Masters Degree in science, pharmacy and pharmaceutical chemistry.